Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Shares Outstanding (2020 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Shares Outstanding for 6 consecutive years, with $166.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding rose 11.23% year-over-year to $166.2 million, compared with a TTM value of $166.2 million through Dec 2025, up 11.23%, and an annual FY2025 reading of $166.2 million, up 11.23% over the prior year.
  • Shares Outstanding was $166.2 million for Q4 2025 at Xeris Biopharma Holdings, roughly flat from $165.5 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $166.2 million in Q4 2025 and bottomed at $66.3 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $133.2 million, with a median of $138.0 million recorded in 2023.
  • The sharpest move saw Shares Outstanding surged 109.48% in 2021, then grew 1.3% in 2023.
  • Year by year, Shares Outstanding stood at $124.9 million in 2021, then rose by 9.13% to $136.3 million in 2022, then rose by 1.36% to $138.1 million in 2023, then increased by 8.18% to $149.4 million in 2024, then rose by 11.23% to $166.2 million in 2025.
  • Business Quant data shows Shares Outstanding for XERS at $166.2 million in Q4 2025, $165.5 million in Q3 2025, and $161.2 million in Q2 2025.